New Jersey hospital’s tax-exempt status challenged by city council

Hackensack University Medical Center could be on the hook to pay back millions in property taxes if the Hackensack, New Jersey, city council gets its way.

According to northjersey.com, the decision was spurred by a 2016 ruling against another hospital, Morristown Medical Center, which paid a settlement $15.5 million after a judge ruled it ran more like for a for-profit business than a charitable institution. Since then, 41 tax challenges have been filed between hospitals and municipalities.

“It wasn’t a precedent-setting case,” said Kerry McKean-Kelly, spokesperson for the New Jersey Hospital Association. “It didn’t automatically become the law of land. But really what it did is created this Wild Wild West among municipalities of tax challenges.”

Hackensack’s tax assessor, Art Carlson, said the hospital does pay as much as $8 million on properties outside its main campus. The move by the council is about making sure the hospital knows “they’re on notice,” Carlson said.

“We appreciate what they’ve done for the city. But we feel we’re entitled to some commensurate payment. You're sitting on 17 acres of prime real estate. Just on the land alone, we need some type of agreement,” he said.

The goal is to figure out a settlement and avoid litigation, Carlson said.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.